Key result
A rapid and sensitive LC-MS/MS method was successfully developed and validated for the simultaneous quantification of pravastatin and aspirin in human plasma, demonstrating its suitability for pharmacokinetic studies.
A rapid and sensitive LC-MS/MS method was successfully developed and validated for the simultaneous quantification of pravastatin and aspirin in human plasma, suitable for clinical pharmacokinetic studies.
A rapid and sensitive liquid chromatography–tandem mass spectrometric (LC–MS/MS) assay method has been developed and fully validated for the simultaneous quantification of pravastatin and aspirin in human plasma. Furosemide was used as an internal standard. Analytes and the internal standard were extracted from human plasma by liquid–liquid extraction technique using methyl tertiary butyl ether. The reconstituted samples were chromatographed on a Zorbax SB-C 18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v) as the mobile phase at a flow rate of 0.8 mL/min. The calibration curve obtained was linear ( r ≥0.99) over the concentration range of 0.50–600.29 ng/mL for pravastatin and 20.07–2012.00 ng/mL for aspirin. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day. The proposed method was found to be applicable to clinical studies.
No takes yet. Share an insight, caveat, or question.
Polagani et al. (2012) studied Healthy (n=12). Pravastatin and Aspirin was evaluated on Pharmacokinetic parameters (Cmax, AUC, tmax, t1/2). A rapid and sensitive LC-MS/MS method was successfully developed and validated for the simultaneous quantification of pravastatin and aspirin in human plasma, demonstrating its suitability for pharmacokinetic studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: